Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vertex PharmaceuticalsXTER:VX1 -0.83%86 Cyclically Adjusted PS Ratio is 15.62 as of Sep. 16, 2026, which is 26% below its 10-year median of 21.05. GuruFocus rates XTER:VX1 with a GF Score™ of 86/100 and a GF Value™ of €460.79 (Fairly Valued). The stock has 4 warning signs investors should review. Among 532 Biotechnology companies, Vertex Pharmaceuticals ranks worse than 75.94% on this metric.
The historical rank and industry rank for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:
XTER:VX1'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 13.63 Med: 21.05 Max: 37.95
Current: 16.13
During the past years, Vertex Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 37.95. The lowest was 13.63. And the median was 21.05.
XTER:VX1's Cyclically Adjusted PS Ratio is ranked worse than 75.94% of 532
companies
in the Biotechnology industry
Industry Median: 5.78
vs XTER:VX1: 16.13
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Vertex Pharmaceuticals's adjusted revenue per share data for the three months ended in Jun. 2026 was €11.270. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €28.55 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Vertex Pharmaceuticals (XTER:VX1) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms
Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Chart
XTER:VX1 vs REGN, MRNA, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
Vertex Pharmaceuticals Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 15.62 mean?
Vertex Pharmaceuticals (XTER:VX1) has a Cyclically Adjusted PS Ratio of 15.62 as of Sep. 16, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors. This is 26% below median its historical median of 21.05. Over the past decade, Vertex Pharmaceuticals' Cyclically Adjusted PS Ratio has ranged from 13.63 to 37.95. According to the industry distribution chart, Vertex Pharmaceuticals ranks #404 out of 532 companies in the Biotechnology industry, placing it in the top 75.9%.
Is Vertex Pharmaceuticals' Cyclically Adjusted PS Ratio too high?
Vertex Pharmaceuticals' current Cyclically Adjusted PS Ratio of 15.62 is 26% below median its 10-year median of 21.05. Over the past 10 years, this metric has ranged from a low of 13.63 to a high of 37.95. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.78. Vertex Pharmaceuticals' value of 15.62 is 170.2% above this industry median. Based on the distribution chart, Vertex Pharmaceuticals ranks #404 out of 532 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vertex Pharmaceuticals has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cyclically Adjusted PS Ratio compare to REGN and MRNA?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #404 out of 532 companies for Cyclically Adjusted PS Ratio. This places Vertex Pharmaceuticals in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.78. Vertex Pharmaceuticals' value of 15.62 is 170.2% above this benchmark. Historically, Vertex Pharmaceuticals' own Cyclically Adjusted PS Ratio has ranged from 13.63 to 37.95 over the past decade. While the company's 10-year median is 21.05 vs. the industry median of 5.78, Vertex Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.78, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vertex Pharmaceuticals's current Cyclically Adjusted PS Ratio of 15.62 is 170.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vertex Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vertex Pharmaceuticals's current Cyclically Adjusted PS Ratio is 15.62, which is 26% below median its own 10-year median of 21.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (XTER:VX1) is currently considered Fairly Valued. The stock's GF Value™ is €460.79, compared to a current price of €445.80 — trading 3.3% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 15.62, which is 26% below median its 10-year median of 21.05 and 170.2% above the Biotechnology industry median of 5.78. Vertex Pharmaceuticals' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Vertex Pharmaceuticals (XTER:VX1), the current Cyclically Adjusted PS Ratio is 15.62 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (XTER:VX1) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of €445.80 is trading 3.3% below its estimated GF Value™ of €460.79.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for XTER:VX1:
Cyclically Adjusted PS Ratio: 15.62 (26% below median its 10-year median of 21.05)
GF Value™: €460.79 vs. price of €445.80 (3.3% below fair value)
Industry Position: 170.2% above the Biotechnology median (#404 of 532)
No single metric tells the full story. See the XTER:VX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
86GF Score
Get the complete analysis for XTER:VX1
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:VX1 has been successfully added to your 
